Ost-müük PhaseBio Pharmaceuticals, Inc. - PHAS CFD
Lisa lemmikuks- Kokkuvõte
- Ajaloolised andmed
- Sündmused
- Tuluaruanne
- Bilanss
- Rahavood
- Omand
Kauplemistingimused
| Hinnavahe | 0.06 | ||||||||
|
Pika positsiooni ööpäeva tasu
Long position overnight fee
Mine platvormile | -0.025457% | ||||||||
|
Lühikese positsiooni ööpäeva tasu
Short position overnight fee
Mine platvormile | 0.003235% | ||||||||
| Ööpäeva tasu aeg | 21:00 (UTC) | ||||||||
| Min kauplemise kogus | 1 | ||||||||
| Valuuta | USD | ||||||||
| Tagatis | 20% | ||||||||
| Aktsiabörs | United States of America | ||||||||
| Kauplemise vahendustasu | 0% |
*Information provided by Capital.com
PhaseBio Pharmaceuticals Inc ESG Risk Ratings
High Medium Low Negligible
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Võtmestatistika
| Eelmine sulgemine* | 0.76 |
| Avatud* | 0.83 |
| Aastane muutus* | 12.16% |
| Päeva ulatus* | 0.73 - 0.85 |
| 52 nädala ulatus | 0.00-1.38 |
| Keskmine maht (10 päeva) | 19.93K |
| Keskmine maht (3 kuud) | 840.88K |
| Turukapitalisatsioon | 29.91K |
| P/E suhtarv | -100.00K |
| Ringluses olevad aktsiad | 49.86M |
| Tulu | 818.00K |
| EPS | -2.13 |
| Dividendid (% kasumist) | N/A |
| Beeta | 2.71 |
| Järgmine tuluaruande kuupäev | Jun 8, 2023 |
Kõigi andmete allikas on Refinitiv, välja arvatud tärniga märgitud, kus *-ga andmed on esitanud Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Sulgemishind | Change (%) | Avamishind | High | Low |
|---|---|---|---|---|---|---|
| Sep 27, 2022 | 0.74 | -0.09 | -10.84% | 0.83 | 0.85 | 0.73 |
| Sep 26, 2022 | 0.76 | 0.01 | 1.33% | 0.75 | 0.80 | 0.75 |
| Sep 23, 2022 | 0.76 | -0.03 | -3.80% | 0.79 | 0.81 | 0.74 |
| Sep 22, 2022 | 0.80 | -0.08 | -9.09% | 0.88 | 0.88 | 0.78 |
| Sep 21, 2022 | 0.87 | -0.07 | -7.45% | 0.94 | 0.96 | 0.87 |
| Sep 20, 2022 | 0.93 | -0.03 | -3.12% | 0.96 | 0.96 | 0.89 |
| Sep 19, 2022 | 0.96 | 0.00 | 0.00% | 0.96 | 0.99 | 0.95 |
| Sep 16, 2022 | 0.99 | -0.02 | -1.98% | 1.01 | 1.06 | 0.94 |
| Sep 15, 2022 | 1.05 | 0.03 | 2.94% | 1.02 | 1.06 | 1.02 |
| Sep 14, 2022 | 1.02 | -0.05 | -4.67% | 1.07 | 1.09 | 1.00 |
| Sep 13, 2022 | 1.05 | -0.02 | -1.87% | 1.07 | 1.08 | 1.04 |
| Sep 12, 2022 | 1.11 | 0.06 | 5.71% | 1.05 | 1.13 | 1.05 |
| Sep 9, 2022 | 1.06 | -0.04 | -3.64% | 1.10 | 1.17 | 1.03 |
| Sep 8, 2022 | 1.09 | 0.06 | 5.83% | 1.03 | 1.09 | 1.03 |
| Sep 7, 2022 | 1.04 | 0.03 | 2.97% | 1.01 | 1.05 | 1.01 |
| Sep 6, 2022 | 1.01 | -0.05 | -4.72% | 1.06 | 1.08 | 1.00 |
| Sep 2, 2022 | 1.06 | -0.06 | -5.36% | 1.12 | 1.12 | 1.01 |
| Sep 1, 2022 | 1.05 | 0.02 | 1.94% | 1.03 | 1.06 | 1.03 |
| Aug 31, 2022 | 1.04 | 0.06 | 6.12% | 0.98 | 1.04 | 0.98 |
| Aug 30, 2022 | 1.00 | -0.05 | -4.76% | 1.05 | 1.07 | 0.98 |
PhaseBio Pharmaceuticals, Inc. Events
| Kellaaeg (UTC) (UTC) | Riik | Sündmus |
|---|---|---|
| Thursday, June 22, 2023 | ||
| Kellaaeg (UTC) (UTC) 10:59 | Riik US
| Sündmus Q4 2022 PhaseBio Pharmaceuticals Inc Earnings Release Q4 2022 PhaseBio Pharmaceuticals Inc Earnings ReleaseForecast -Previous - |
| Kellaaeg (UTC) (UTC) 12:30 | Riik US
| Sündmus Q1 2023 PhaseBio Pharmaceuticals Inc Earnings Release Q1 2023 PhaseBio Pharmaceuticals Inc Earnings ReleaseForecast -Previous - |
| Thursday, August 10, 2023 | ||
| Kellaaeg (UTC) (UTC) 12:30 | Riik US
| Sündmus Q2 2023 PhaseBio Pharmaceuticals Inc Earnings Release Q2 2023 PhaseBio Pharmaceuticals Inc Earnings ReleaseForecast -Previous - |
- Aastas
- Kvartalis
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Kogutulu | 10.831 | 0.32 | 2.361 | 0.668 | 0 |
| Kogu tegevuskulu | 118.193 | 85.176 | 42.097 | 20.312 | 8.538 |
| Müük/Üldine/admin kulud, kokku | 16.086 | 13.088 | 11.186 | 4.857 | 2.328 |
| Uuringud ja arendus | 102.107 | 72.088 | 30.911 | 15.455 | 6.21 |
| Tulud majandustegevusest | -107.362 | -84.856 | -39.736 | -19.644 | -8.538 |
| Intressitulud (kulu), muud tulud, neto | -22.109 | -13.709 | 0.489 | -4.213 | -2.728 |
| Muud, neto | 0 | 0.011 | 1.019 | ||
| Netotulu enne makse | -129.471 | -98.565 | -39.247 | -23.846 | -10.247 |
| Netotulu pärast makse | -131.071 | -98.565 | -39.247 | -23.846 | -10.247 |
| Netotulu enne erikulusid | -131.071 | -98.565 | -39.247 | -23.846 | -10.247 |
| Netotulu | -131.071 | -98.565 | -39.247 | -23.846 | -10.247 |
| Arvestatav tulu, v a erikulud | -131.071 | -98.565 | -39.247 | -23.846 | -10.247 |
| Arvestatav tulu, koos erikuludega | -131.071 | -98.565 | -39.247 | -23.846 | -10.247 |
| Jaotamisele kuuluv netotulu | -131.071 | -98.565 | -39.247 | -23.846 | -10.247 |
| Keskmine jaotamisele kuuluv aktsia kohta | 43.919 | 29.0563 | 27.4936 | 24.4983 | 19.5884 |
| Jaotatav EPS, v a erakorralised kulud | -2.98438 | -3.39221 | -1.4275 | -0.97337 | -0.52312 |
| Dividends per Share - Common Stock Primary Issue | 0 | ||||
| Jaotamisele kuuluv normaal-EPS | -2.98438 | -3.39221 | -1.4275 | -0.97337 | -0.52312 |
| Erakorralised kulud kokku | 0 | 0 | |||
| Tulu | 10.831 | 0.32 | 2.361 | 0.668 |
| Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | |
|---|---|---|---|---|---|
| Kogutulu | 0.208 | 0.117 | 0.158 | 0.335 | 10.338 |
| Tulu | 0.208 | 0.117 | 0.158 | 0.335 | 10.338 |
| Kogu tegevuskulu | 25.52 | 18.345 | 32.244 | 28.911 | 31.391 |
| Müük/Üldine/admin kulud, kokku | 4.581 | 4.009 | 4.889 | 3.845 | 4.025 |
| Uuringud ja arendus | 20.939 | 14.336 | 27.355 | 25.066 | 27.366 |
| Tulud majandustegevusest | -25.312 | -18.228 | -32.086 | -28.576 | -21.053 |
| Intressitulud (kulu), muud tulud, neto | 8.647 | 7.087 | -11.024 | -3.348 | -6.026 |
| Netotulu enne makse | -16.665 | -11.141 | -43.11 | -31.924 | -27.079 |
| Netotulu pärast makse | -16.665 | -11.141 | -43.11 | -31.924 | -28.679 |
| Netotulu enne erikulusid | -16.665 | -11.141 | -43.11 | -31.924 | -28.679 |
| Netotulu | -16.665 | -11.141 | -43.11 | -31.924 | -28.679 |
| Arvestatav tulu, v a erikulud | -16.665 | -11.141 | -43.11 | -31.924 | -28.679 |
| Arvestatav tulu, koos erikuludega | -16.665 | -11.141 | -43.11 | -31.924 | -28.679 |
| Jaotamisele kuuluv netotulu | -16.665 | -11.141 | -43.11 | -31.924 | -28.679 |
| Keskmine jaotamisele kuuluv aktsia kohta | 49.1828 | 48.635 | 48.1769 | 48.0463 | 47.9859 |
| Jaotatav EPS, v a erakorralised kulud | -0.33884 | -0.22907 | -0.89483 | -0.66444 | -0.59766 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Jaotamisele kuuluv normaal-EPS | -0.33884 | -0.22907 | -0.89483 | -0.66444 | -0.59766 |
- Aastas
- Kvartalis
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Käibevarad kokku | 48.784 | 40.149 | 78.823 | 62.628 | 13.746 |
| Raha ja lühiajalised investeeringud | 41.8 | 28.122 | 74.025 | 61.031 | 13.406 |
| Raha ja ekvivalendid | 41.8 | 28.122 | 74.025 | 61.031 | 13.406 |
| Prepaid Expenses | 6.984 | 12.027 | 3.565 | 1.344 | 0.32 |
| Other Current Assets, Total | 0 | 0.02 | 0.02 | ||
| Total Assets | 60.54 | 50.357 | 82.494 | 63.026 | 14.099 |
| Property/Plant/Equipment, Total - Net | 11.699 | 10.151 | 3.639 | 0.355 | 0.302 |
| Property/Plant/Equipment, Total - Gross | 15.619 | 12.277 | 5.598 | 2.14 | 1.947 |
| Accumulated Depreciation, Total | -3.92 | -2.126 | -1.959 | -1.785 | -1.645 |
| Other Long Term Assets, Total | 0.057 | 0.057 | 0.032 | 0.043 | 0.051 |
| Total Current Liabilities | 27.883 | 14.96 | 8.479 | 4.577 | 17.595 |
| Accounts Payable | 12.57 | 3.674 | 2.921 | 1.806 | 0.43 |
| Accrued Expenses | 8.353 | 5.931 | 3.18 | 2.771 | 1.281 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 12.095 |
| Current Port. of LT Debt/Capital Leases | 5.413 | 5.355 | 2.378 | 0 | 0.761 |
| Other Current Liabilities, Total | 1.547 | 0 | 3.028 | ||
| Total Liabilities | 153.574 | 75.559 | 22.516 | 12.099 | 21.881 |
| Total Long Term Debt | 1.359 | 6.773 | 12.326 | 7.5 | 4.281 |
| Long Term Debt | 1.359 | 6.773 | 12.326 | 7.5 | 4.281 |
| Other Liabilities, Total | 124.332 | 53.826 | 1.711 | 0.022 | 0.005 |
| Total Equity | -93.034 | -25.202 | 59.978 | 50.927 | -7.782 |
| Redeemable Preferred Stock | 0 | 0 | 0 | 0 | |
| Common Stock | 0.048 | 0.029 | 0.029 | 0.025 | 0.001 |
| Additional Paid-In Capital | 298.736 | 235.516 | 222.131 | 173.837 | 1.672 |
| Retained Earnings (Accumulated Deficit) | -391.794 | -260.723 | -162.158 | -122.911 | -99.065 |
| Treasury Stock - Common | -0.024 | -0.024 | -0.024 | -0.024 | -0.024 |
| Total Liabilities & Shareholders’ Equity | 60.54 | 50.357 | 82.494 | 63.026 | 14.099 |
| Total Common Shares Outstanding | 48.1906 | 29.4419 | 28.7664 | 24.4983 | 19.5884 |
| Preferred Stock - Non Redeemable, Net | 89.634 | ||||
| Laekumata arved, neto | 0 | 1.233 | 0.233 |
| Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | |
|---|---|---|---|---|---|
| Käibevarad kokku | 11.564 | 27.569 | 48.784 | 65.241 | 88.5 |
| Raha ja lühiajalised investeeringud | 7.804 | 18.688 | 41.8 | 56.357 | 64.456 |
| Raha ja ekvivalendid | 7.804 | 18.688 | 41.8 | 56.357 | 64.456 |
| Prepaid Expenses | 3.76 | 8.881 | 6.984 | 8.884 | 5.644 |
| Total Assets | 22.166 | 38.664 | 60.54 | 77.725 | 100.637 |
| Property/Plant/Equipment, Total - Net | 10.544 | 11.038 | 11.699 | 12.427 | 12.08 |
| Property/Plant/Equipment, Total - Gross | 15.668 | 15.559 | 15.619 | 15.74 | 15.262 |
| Accumulated Depreciation, Total | -5.124 | -4.521 | -3.92 | -3.313 | -3.182 |
| Other Long Term Assets, Total | 0.058 | 0.057 | 0.057 | 0.057 | 0.057 |
| Total Current Liabilities | 24.679 | 21.688 | 27.883 | 21.457 | 16.174 |
| Accounts Payable | 6.32 | 6.778 | 12.57 | 8.521 | 2.958 |
| Accrued Expenses | 12.886 | 7.891 | 8.353 | 6.123 | 6.408 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 4.073 | 5.425 | 5.413 | 5.399 | 5.384 |
| Total Liabilities | 139.564 | 141.059 | 153.574 | 128.054 | 119.812 |
| Total Long Term Debt | 0 | 0 | 1.359 | 2.718 | 4.073 |
| Long Term Debt | 0 | 0 | 1.359 | 2.718 | 4.073 |
| Other Liabilities, Total | 114.885 | 119.371 | 124.332 | 103.879 | 99.565 |
| Total Equity | -117.398 | -102.395 | -93.034 | -50.329 | -19.175 |
| Redeemable Preferred Stock | 0 | 0 | 0 | 0 | 0 |
| Common Stock | 0.05 | 0.049 | 0.048 | 0.048 | 0.048 |
| Additional Paid-In Capital | 302.176 | 300.515 | 298.736 | 298.331 | 297.561 |
| Retained Earnings (Accumulated Deficit) | -419.6 | -402.935 | -391.794 | -348.684 | -316.76 |
| Treasury Stock - Common | -0.024 | -0.024 | -0.024 | -0.024 | -0.024 |
| Total Liabilities & Shareholders’ Equity | 22.166 | 38.664 | 60.54 | 77.725 | 100.637 |
| Total Common Shares Outstanding | 49.8581 | 48.6906 | 48.1906 | 48.0625 | 48.0277 |
| Laekumata arved, neto | 18.4 | ||||
| Other Current Liabilities, Total | 1.4 | 1.594 | 1.547 | 1.414 | 1.424 |
- Aastas
- Kvartalis
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Netotulu/algväärtus | -131.071 | -98.565 | -39.247 | -23.846 | -10.247 |
| Raha majandustegevusest | -47.416 | -59.957 | -39.594 | -17.053 | -8.259 |
| Raha majandustegevusest | 1.793 | 0.508 | 0.174 | 0.105 | 0.096 |
| Mittelikviidsed varad | 52.494 | 42.362 | 1.921 | 4.661 | 1.826 |
| Makstud intressid | 0.517 | 0.954 | 0.576 | 0.26 | 0.012 |
| Muutused tööjõus | 29.368 | -4.262 | -2.442 | 2.027 | 0.066 |
| Tulu investeeringutelt | -2.679 | -1.412 | -0.96 | -0.119 | -0.216 |
| Kapitalikulutused | -2.679 | -1.412 | -0.96 | -0.119 | -0.216 |
| Muud rahavood investeeringutelt, kokku | 0 | ||||
| Rahavood investeeringutelt | 63.773 | 15.466 | 53.528 | 64.797 | 18.166 |
| Aktsiate emiteerimine (tagasiost), neto | 61.084 | 3.223 | 46.522 | 60.802 | 0.003 |
| Laenu väljastamine (kustutamine), neto | -5.455 | -2.727 | 7.151 | 3.995 | 18.163 |
| Rahaline kogumuutus | 13.678 | -45.903 | 12.974 | 47.625 | 9.691 |
| Rahavoogudesse investeerimine | 8.144 | 14.97 | -0.145 |
| Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -27.806 | -11.141 | -131.071 | -87.961 | -56.037 |
| Cash From Operating Activities | -33.295 | -22.884 | -47.416 | -27.422 | -21.29 |
| Cash From Operating Activities | 1.204 | 0.601 | 1.793 | 1.187 | 1.057 |
| Non-Cash Items | -7.168 | -3.257 | 52.494 | 37.979 | 32.479 |
| Cash Interest Paid | 0.187 | 0.104 | 0.517 | 0.517 | 0.366 |
| Changes in Working Capital | 0.475 | -9.087 | 29.368 | 21.373 | 1.211 |
| Cash From Investing Activities | -0.107 | -0.049 | -2.679 | -1.023 | -0.385 |
| Capital Expenditures | -0.107 | -0.049 | -2.679 | -1.023 | -0.385 |
| Cash From Financing Activities | -0.594 | -0.179 | 63.773 | 56.68 | 58.009 |
| Financing Cash Flow Items | 0 | 8.144 | -0.04 | -0.04 | |
| Issuance (Retirement) of Stock, Net | 2.133 | 1.185 | 61.084 | 60.811 | 60.776 |
| Issuance (Retirement) of Debt, Net | -2.727 | -1.364 | -5.455 | -4.091 | -2.727 |
| Net Change in Cash | -33.996 | -23.112 | 13.678 | 28.235 | 36.334 |
| Investori nimi | Investori liik | Ringluse protsent | Hoitud osakud | Muutus osakutes | Hoidmise kuupäev | Hinnang käibele |
|---|---|---|---|---|---|---|
| AstraZeneca PLC | Corporation | 5.8983 | 2940804 | -63750 | 2022-03-31 | LOW |
| Hatteras Venture Partners | Venture Capital | 4.8396 | 2412919 | 0 | 2022-03-31 | LOW |
| Rosalind Advisors, Inc. | Hedge Fund | 1.419 | 707467 | -1900390 | 2021-12-31 | |
| Mow (Jonathan P.) | Individual Investor | 0.3684 | 183701 | 10918 | 2022-05-20 | |
| van den Broek (Richard A) | Individual Investor | 0.1354 | 67500 | 3750 | 2023-05-19 | |
| Sharp (John P) | Individual Investor | 0.1319 | 65767 | 6026 | 2022-05-20 | |
| Hutson (Nancy J) | Individual Investor | 0.0833 | 41510 | 3750 | 2023-05-19 | |
| Arnold (Susan Elizabeth) | Individual Investor | 0.0827 | 41236 | 10917 | 2022-05-20 | |
| Thorp (Clay B.) | Individual Investor | 0.0736 | 36693 | 3750 | 2023-05-19 | MED |
| Birchall (Jonathan) | Individual Investor | 0.0401 | 20000 | 20000 | 2022-05-20 | |
| Harrigan (Edmund P. M.D.) | Individual Investor | 0.0196 | 9750 | 3750 | 2023-05-19 | LOW |
| Hanson (Kristopher) | Individual Investor | 0.017 | 8463 | 4831 | 2022-05-20 | |
| BlackRock Advisors, LLC | Investment Advisor/Hedge Fund | 0.014 | 6971 | 0 | 2022-12-31 | MED |
| BlackRock Fund Advisors | Investment Advisor | 0.014 | 6971 | 0 | 2022-06-30 | LOW |
| Sapir (Alex) | Individual Investor | 0.0075 | 3750 | 3750 | 2023-05-19 | |
| Loewy (Caroline M) | Individual Investor | 0.0075 | 3750 | 3750 | 2023-05-19 | |
| Humphries (William Douglas) | Individual Investor | 0.0051 | 2538 | 2538 | 2023-05-19 | LOW |
Miks valida Capital.com? Meie numbrid räägivad iseenda eest.
Capital.com Group535K+
Kauplejad
87K+
Igakuiste aktiivsete klientide arv
$113M+
Igakuine investeerimise maht
$64M+
Igakuiselt välja võetud
Kauplemiskalkulaator
Arvutage oma hüpoteetiline võit/kaotus, kui oleksite avanud CFD-tehingu ühel kindlal kuupäeval (valige kuupäev) ja sulgenud teisel kuupäeval (valige kuupäev).
Kauplemise vahendustasu
0
- 1:1
Finantsvõimendus
1:1
- 20
- 100
- 500
- 1000
- 10000
Investeering
Tehingu suurus (võimendus x investeering):
Avamishind
Close
Lühike Pikk
PhaseBio Pharmaceuticals, Inc. Company profile
Ettevõttest PhaseBio Pharmaceuticals, Inc.
PhaseBio Pharmaceuticals, Inc. on kliinilise faasi biofarmatseutiline ettevõte. Ettevõte keskendub kardiopulmonaalsete haiguste ravimeetodite väljatöötamisele ja turustamisele. Ettevõtte juhtiv tootekandidaat bentrakimab (PB2452) on trombotsüütide vastase ravimi ticagrelori pöördravim, mida ettevõte arendab ticagrelori trombotsüütide vastase toime tühistamiseks patsientidel, kellel on kontrollimatu suur või eluohtlik verejooks või kes vajavad kiiret operatsiooni või invasiivset protseduuri. Ettevõtte teine tootekandidaat, pemziviptadil (PB1046), on II faasi arenduses pulmonaalse arteriaalse hüpertensiooni (PAH) raviks. Pemziviptadil kasutab ettevõtte poolväärtusaega pikendavat elastiinitaolist polüpeptiidi tehnoloogiat, mis on ka ettevõtte prekliinilise tooteprogrammi mootoriks. Ettevõte arendab ka oma prekliinilist tootekandidaati PB6440 raviresistentse hüpertensiooni raviks.
| Industry: | Bio Therapeutic Drugs |
1 Great Valley Pkwy Ste 30
19355-1423
Tuluaruanne
- Annual
- Quarterly
Teised on vaadanud veel
Kas otsite jätkuvalt vahendajat, keda saab usaldada?
Ühinege 535,000+ kauplejaga üle kogu maailma, kes valisid kauplemiseks veebisaidi Capital.com